Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Specific immunotherapy in pollen allergy.

Michael Wallner1, Peter Briza, Josef Thalhamer

  • 1Christian Doppler Laboratory for Allergy Diagnosis and Therapy, Department of Molecular Biology, University of Salzburg, Hellbrunnerstralle 34, A-5020 Salzburg, Austria.

Current Opinion in Molecular Therapeutics
|April 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ozone alters the allergenicity of Ambrosia artemisiifolia pollen in a dose-dependent manner.

Environment international·2026
Same author

Multi-country IgE reactivity determination of isoforms of the <i>Blomia tropicalis</i> mite allergen Blo t 2 revealed a potential biomarker of asthma severity.

Frontiers in immunology·2026
Same author

Maternal-infant immune signatures in infants at risk for SARS-CoV-2-associated neurodevelopmental disorders.

Communications biology·2026
Same author

Engineering Chimeric Hypoallergens for Safer and More Effective House Dust Mite Allergy Vaccines.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2025
Same author

Evaluation of Inhibitory Activity of Novel Monoclonal Antibodies Against Cat Allergen Fel d 7 and Their Application to Analyse Allergen Extracts.

Scandinavian journal of immunology·2025
Same author

Conformational plasticity of β-rich proteins: Molecular insights into stability, dynamics, and functional adaptation of Bet v 1-like proteins.

International journal of biological macromolecules·2025
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Allergen-specific immunotherapy (SIT) effectively treats pollen allergies and prevents asthma development. New recombinant allergen formulations show promise for improved treatment of hay fever and allergic rhinitis.

Area of Science:

  • Immunology
  • Allergology
  • Respiratory Medicine

Background:

  • Pollen allergy impacts over 10% globally, with a significant risk of developing allergic asthma.
  • Allergen-specific immunotherapy (SIT) is effective for seasonal allergic rhinitis, preventing new sensitizations and asthma.
  • Current SIT uses pollen extracts, but research is exploring improved formulations.

Purpose of the Study:

  • To review the efficacy of allergen-specific immunotherapy (SIT) for pollen allergies.
  • To explore novel approaches for enhancing SIT efficacy and reducing adverse reactions.
  • To discuss the potential of new molecule-based formulations for pollen allergy management.

Main Methods:

  • Review of clinical studies on SIT for seasonal allergic rhinitis.

Related Experiment Videos

  • Investigation of chemically modified, recombinant, or genetically engineered allergens.
  • Exploration of novel adjuvants and alternative administration routes for immunotherapy.

    • Main Results:

    • SIT efficacy is confirmed for grass, ragweed, and birch pollen allergies.
    • SIT prevents new allergen sensitizations and reduces asthma development.
    • Early clinical trials with recombinant allergens show promising results, suggesting extract substitution.

    Conclusions:

    • SIT is a valuable treatment for pollen allergies and prevention of allergic asthma.
    • Novel approaches, including recombinant allergens, aim to improve SIT safety and efficacy.
    • Molecule-based formulations are expected to advance the routine management of pollen allergies soon.